The Very Large Database of Lipids (VLDL)
Ключови думи
Резюме
Описание
REGISTRATION & STATUS OF VLDL STUDIES
- VLDL-1A: Friedewald Estimated versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications (abstract presented; manuscript published; citation provided below)
- VLDL-1B: Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels from the Standard Lipid Profile (manuscript published; citation provided below)
- VLDL-1C: Low-Density Lipoprotein Cholesterol Estimation at Very Low Levels and Clinical Implications (abstract presented; manuscript published; citation provided below)
- VLDL-1D: Fasting vs non-fasting impact on low-density lipoprotein-cholesterol accuracy (abstract presented; manuscript published; citation provided below)
- VLDL-2A: Non-High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention (abstract presented; manuscript published; citation provided below)
- VLDL-2B: Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol (abstract presented; manuscript published; citation provided below)
- VLDL-3: Deficient Serum 25-Hydroxy Vitamin D is Associated with an Atherogenic Lipid Profile (abstract presented; manuscript published; citation provided below)
- VLDL-4: Relationship of the Triglyceride to High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio to the Remainder of the Lipid Profile (abstract presented; manuscript published; citation provided below)
- VLDL-5: Ratio of Dense to Buoyant LDL Subclass and LDL Density Phenotype (abstract presented; manuscript published; citation provided below)
- VLDL-6: Characterization of Fredrickson-Levy Dyslipidemia Classes without Chylomicrons (IIa, IIb, III,IV) (abstract presented; manuscript in preparation)
- VLDL-7: Characterization of Fredrickson-Levy Dyslipidemia Classes with Chylomicrons (I,V) (abstract presented; manuscript in preparation)
- VLDL-8: Continuum of Non-Chylomicron Dyslipidemia Phenotype not Classifiable by Fredrickson-Levy Criteria (abstract presented; manuscript in preparation)
- VLDL-9: Lipid Phenotypes at the Extremes of High-Density Lipoprotein Cholesterol (abstract presented; manuscript published; citation provided below)
- VLDL-10A: Atherogenic Lipid Levels in 662,711 Elderly Persons: The Very Large Database of Lipids 10A (abstract presented; manuscript in preparation)
- VLDL-10B: Narrowing Sex Differences in Lipoprotein Cholesterol Subclasses Following Mid-Life (abstract presented; manuscript published; citation provided below)
- VLDL-11: Exploration of individuals with American Heart Association (AHA) ideal total cholesterol (<200 mg/dL) (statistical analysis plan in development)
- VLDL-12: Extremely low LDL-C, non-HDL-C phenotype (statistical analysis plan in development)
- VLDL-13: Thyroid function vs. lipids (abstract presented; manuscript in preparation)
- VLDL-14: Seasonal variation in lipids and biomarkers (abstract presented; manuscript in preparation)
- VLDL-15: Lipids, hsCRP, Lp(a), Lp-PLA2: phenotypes, lipid oxidation, inflammation (statistical analysis plan in development)
- VLDL-16: Secular trends in metabolic syndrome lipid criteria, remnant lipoprotein cholesterol (statistical analysis plan in development)
- VLDL-17: Screening for familial hypercholesterolemia (abstract presented; manuscript published; citation provided below)
- VLDL-18: Remnant Lipoprotein Cholesterol definitions (statistical analysis plan in development)
- VLDL-19: Lipoprotein(a) in familial hypercholesterolemia (statistical analysis plan in development)
- VLDL-20: Lipoprotein subfractions and uric acid (abstract in preparation)
- VLDL-21: Lipoprotein subfractions and homocysteine (abstract presented; manuscript published; citation provided below)
- VLDL-22: Lipoprotein(a), HDL-C, and TG (abstract presented; manuscript in preparation)
- VLDL-23: Dual LDL-C and hs-CRP target attainment (abstract presented; manuscript in preparation)
Дати
Последна проверка: | 12/31/2019 |
Първо изпратено: | 09/30/2012 |
Очаквано записване подадено: | 10/01/2012 |
Първо публикувано: | 10/02/2012 |
Изпратена последна актуализация: | 01/07/2020 |
Последна актуализация публикувана: | 01/12/2020 |
Действителна начална дата на проучването: | 03/31/2006 |
Приблизителна дата на първично завършване: | 03/31/2026 |
Очаквана дата на завършване на проучването: | 03/31/2026 |
Състояние или заболяване
Фаза
Критерии за допустимост
Полове, допустими за проучване | All |
Метод за вземане на проби | Non-Probability Sample |
Приема здрави доброволци | Да |
Критерии | Patients with age and lipid data are included in the master database. Eligibility criteria are specific to each individual study. |
Резултат
Първични изходни мерки
1. all-cause mortality [up to 9 years from time of baseline lipid profile]